CASTANEDO, GEORGETTE,卡斯坦杜 乔葛特,卡斯坦杜 喬葛特,FENG, JIANWEN,冯 强文,馮 強文,MONTALBETTI, CHRISTIAN A. G. N.,蒙特贝提 克力斯俊Ａ Ｇ Ｎ,蒙特貝提 克力斯俊Ａ Ｇ Ｎ,STABEN, STEVEN,史塔班 史帝文,卡斯坦杜 乔葛特,卡斯坦杜 喬葛特,冯 强文,馮 強文,蒙特贝提 克力斯俊A G N,蒙特貝提 克力斯俊A G N,史塔班 史帝文
申请号：
TW102105673
公开号：
TW201336827A
申请日:
2013.02.18
申请国别(地区):
TW
年份:
2013
代理人:
摘要：
The invention relates to novel compounds of Formula I: wherein A1, A2, A3, A4, A5, A6, R2, R4, R5, R6, R7, R8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.本發明係關於新穎式I化合物：其中A1、A2、A3、A4、A5、A6、R2、R4、R5、R6、R7、R8及下標m及n各自具有如本文所述之含義。式I化合物及其醫藥組合物適用於治療其中觀測到不當或過度活化之NF-kB信號傳導之疾病及病症。
